QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
QQQ   305.52 (+0.41%)
AAPL   122.25 (-0.56%)
MSFT   214.36 (+0.06%)
FB   279.70 (-0.76%)
GOOGL   1,823.76 (+0.11%)
AMZN   3,162.58 (-0.76%)
TSLA   599.04 (+0.95%)
NVDA   542.33 (+1.21%)
BABA   267.25 (+0.13%)
CGC   28.59 (-0.14%)
GE   10.88 (+2.64%)
MU   73.34 (+4.92%)
AMD   94.04 (+1.87%)
T   29.54 (+1.06%)
NIO   43.04 (-5.09%)
F   9.34 (+1.41%)
ACB   10.89 (-3.11%)
BA   232.71 (-1.89%)
NFLX   498.31 (+0.16%)
GILD   61.56 (+1.15%)
DIS   154.14 (+0.59%)
Log in
NASDAQ:CASI

CASI Pharmaceuticals Stock Forecast, Price & News

$2.43
+0.05 (+2.10 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$2.32
Now: $2.43
$2.45
50-Day Range
$1.60
MA: $2.03
$2.58
52-Week Range
$1.15
Now: $2.43
$3.32
Volume175,794 shs
Average Volume340,734 shs
Market Capitalization$301.18 million
P/E RatioN/A
Dividend YieldN/A
Beta0.41
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited, Juventas Cell Therapy Ltd., and Pharmathen Global BV. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.
CASI Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CASI
CUSIPN/A
Phone240-864-2600
Employees125

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.13 million
Book Value$0.74 per share

Profitability

Net Income$-46,030,000.00
Net Margins-402.87%

Miscellaneous

Market Cap$301.18 million
Next Earnings Date3/15/2021 (Estimated)
OptionableNot Optionable
$2.43
+0.05 (+2.10 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CASI News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions

How has CASI Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

CASI Pharmaceuticals' stock was trading at $1.63 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CASI stock has increased by 49.1% and is now trading at $2.43.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of CASI Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CASI Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than CASI Pharmaceuticals?

Wall Street analysts have given CASI Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CASI Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is CASI Pharmaceuticals' next earnings date?

CASI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for CASI Pharmaceuticals
.

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) posted its quarterly earnings results on Saturday, November, 14th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.08. CASI Pharmaceuticals had a negative net margin of 402.87% and a negative return on equity of 60.96%.
View CASI Pharmaceuticals' earnings history
.

What price target have analysts set for CASI?

2 equities research analysts have issued 1 year price targets for CASI Pharmaceuticals' stock. Their forecasts range from $3.50 to $5.00. On average, they expect CASI Pharmaceuticals' share price to reach $4.25 in the next twelve months. This suggests a possible upside of 74.9% from the stock's current price.
View analysts' price targets for CASI Pharmaceuticals
.

Are investors shorting CASI Pharmaceuticals?

CASI Pharmaceuticals saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 1,770,000 shares, an increase of 22.1% from the October 15th total of 1,450,000 shares. Based on an average trading volume of 399,700 shares, the short-interest ratio is presently 4.4 days. Approximately 2.4% of the shares of the company are sold short.
View CASI Pharmaceuticals' Short Interest
.

Who are some of CASI Pharmaceuticals' key competitors?

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Blockchain (RIOT), The Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).

Who are CASI Pharmaceuticals' key executives?

CASI Pharmaceuticals' management team includes the following people:
  • Dr. Wei-Wu He, Chairman & CEO (Age 55, Pay $810.83k)
  • Dr. Wei Zhang Ph.D., Pres & Interim Principal Financial Officer (Age 61, Pay $506.1k)
  • Dr. Alexander A. Zukiwski, Chief Medical Officer (Age 63, Pay $535.35k)
  • Ms. Cynthia Wong Hu, COO, Gen. Counsel & Sec. (Age 50)
  • Ms. Sara B. Capitelli, VP of Fin. & Principal Accounting Officer (Age 54)
  • Dr. James E. Goldschmidt, Sr. VP of Bus. Devel.

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (5.57%), Consonance Capital Management LP (5.29%), BlackRock Inc. (2.83%), State Street Corp (0.82%), Charles Schwab Investment Management Inc. (0.38%) and Boothbay Fund Management LLC (0.16%). Company insiders that own CASI Pharmaceuticals stock include Brian D Coleman, Larry Zhang and Wei-Wu He.
View institutional ownership trends for CASI Pharmaceuticals
.

Which major investors are selling CASI Pharmaceuticals stock?

CASI stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, and The Manufacturers Life Insurance Company .
View insider buying and selling activity for CASI Pharmaceuticals
.

Which major investors are buying CASI Pharmaceuticals stock?

CASI stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Consonance Capital Management LP, Charles Schwab Investment Management Inc., State Street Corp, Boothbay Fund Management LLC, BlackRock Inc., GSA Capital Partners LLP, and Squarepoint Ops LLC. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include Brian D Coleman, Larry Zhang, and Wei-Wu He.
View insider buying and selling activity for CASI Pharmaceuticals
.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CASI Pharmaceuticals' stock price today?

One share of CASI stock can currently be purchased for approximately $2.43.

How big of a company is CASI Pharmaceuticals?

CASI Pharmaceuticals has a market capitalization of $301.18 million and generates $4.13 million in revenue each year. The biotechnology company earns $-46,030,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. CASI Pharmaceuticals employs 125 workers across the globe.

What is CASI Pharmaceuticals' official website?

The official website for CASI Pharmaceuticals is www.casipharmaceuticals.com.

How can I contact CASI Pharmaceuticals?

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.